Cornell R B, Kalmar G B, Kay R J, Johnson M A, Sanghera J S, Pelech S L
Institute of Molecular Biology, Simon Fraser University, Burnaby, British Columbia, Canada.
Biochem J. 1995 Sep 1;310 ( Pt 2)(Pt 2):699-708. doi: 10.1042/bj3100699.
The role of the C-terminal domain of CTP: phosphocholine cytidylyltransferase (CT) was explored by the creation of a series of deletion mutations in rat liver cDNA, which were expressed in COS cells as a major protein component. Deletion of up to 55 amino acids from the C-terminus had no effect on the activity of the enzyme, its stimulation by lipid vesicles or on its intracellular distribution between soluble and membrane-bound forms. However, deletion of the C-terminal 139 amino acids resulted in a 90% decrease in activity, loss of response to lipid vesicles and a significant decrease in the fraction of membrane-bound enzyme. Identification of the domain that is phosphorylated in vivo was determined by analysis of 32P-labelled CT mutants and by chymotrypsin proteolysis of purified CT that was 32P-labelled in vivo. Phosphorylation was restricted to the C-terminal 52 amino acids (domain P) and occurred on multiple sites. CT phosphorylation in vitro was catalysed by casein kinase II, cell division control 2 kinase (cdc2 kinase), protein kinases C alpha and beta II, and glycogen synthase kinase-3 (GSK-3), but not by mitogen-activated kinase (MAP kinase). Casein kinase II phosphorylation was directed exclusively to Ser-362. The sites phosphorylated by cdc2 kinase and GSK-3 were restricted to several serines within three proline-rich motifs of domain P. Sites phosphorylated in vitro by protein kinase C, on the other hand, were distributed over the N-terminal catalytic as well as the C-terminal regulatory domain. The stoichiometry of phosphorylation catalysed by any of these kinases was less than 0.2 mol P/mol CT, and no effects on enzyme activity were detected. This study supports a tripartite structure for CT with an N-terminal catalytic domain and a C-terminal regulatory domain comprised of a membrane-binding domain (domain M) and a phosphorylation domain (domain P). It also identifies three kinases as potential regulators in vivo of CT, casein kinase II, cyclin-dependent kinase and GSK-3.
通过在大鼠肝脏cDNA中创建一系列缺失突变,研究了CTP:磷酸胆碱胞苷转移酶(CT)C末端结构域的作用,这些突变在COS细胞中作为主要蛋白质成分表达。从C末端缺失多达55个氨基酸对酶的活性、脂质囊泡对其的刺激作用或其在可溶性和膜结合形式之间的细胞内分布均无影响。然而,缺失C末端的139个氨基酸导致活性降低90%,对脂质囊泡的反应丧失,且膜结合酶的比例显著降低。通过分析32P标记的CT突变体以及对体内进行32P标记的纯化CT进行胰凝乳蛋白酶蛋白水解,确定了体内磷酸化的结构域。磷酸化仅限于C末端的52个氨基酸(结构域P),且发生在多个位点。体外CT的磷酸化由酪蛋白激酶II、细胞分裂控制2激酶(cdc2激酶)、蛋白激酶Cα和βII以及糖原合酶激酶-3(GSK-3)催化,但不由丝裂原活化激酶(MAP激酶)催化。酪蛋白激酶II的磷酸化仅针对Ser-362。cdc2激酶和GSK-3磷酸化的位点仅限于结构域P的三个富含脯氨酸基序内的几个丝氨酸。另一方面,蛋白激酶C在体外磷酸化的位点分布在N末端催化结构域以及C末端调节结构域。这些激酶中任何一种催化的磷酸化化学计量均小于0.2 mol P/mol CT,且未检测到对酶活性的影响。本研究支持CT具有三方结构,即N末端催化结构域和C末端调节结构域,后者由膜结合结构域(结构域M)和磷酸化结构域(结构域P)组成。它还确定了三种激酶作为CT在体内的潜在调节因子,即酪蛋白激酶II、细胞周期蛋白依赖性激酶和GSK-3。